Akihiro et al. showed that trastuzumab deruxtecan is more effective than standard chemotherapy (FOLFOX) in difficult-to-treat HER2+ cases of cholangiocarcinoma. The gene discussed is ERBB2; the disease is cholangiocarcinoma.